Why some clear cell cancers respond to immunotherapy
Systems analysis of mechanisms driving response to immunotherapy in clear cell cancers
['FUNDING_U01'] · STANFORD UNIVERSITY · NIH-11174324
Researchers will map tumor and immune cells in clear cell ovarian and kidney cancers to help identify who might benefit from immune checkpoint drugs.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11174324 on ClinicalTrials.gov |
What this research studies
We will study tumor tissue from people with clear cell ovarian and clear cell renal cancers using detailed molecular profiling and spatial imaging to see which cells are where. The team will combine this with computational and Bayesian machine-learning methods to find patterns linking cell types and their organization to responses to immunotherapy. The work compares clear cell cancers across organs to find shared features that might predict treatment benefit. Tissue samples, biopsies, and clinical data from patients will be integrated to build models that could guide future patient selection for immune therapies.
Who could benefit from this research
Good fit: Ideal candidates are people with clear cell ovarian cancer or clear cell renal cell carcinoma who can provide tumor tissue samples or who are being considered for immune checkpoint treatment.
Not a fit: Patients with non–clear-cell cancers or those unable to provide tumor samples are unlikely to receive direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could help doctors predict which clear cell cancer patients are likely to respond to immunotherapy and personalize treatment choices.
How similar studies have performed: Immune checkpoint therapies already help some clear cell kidney and ovarian cancer patients, and spatial molecular approaches have shown promise in other cancers, but applying these combined systems methods specifically to clear cell cancers is relatively new.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GENTLES, ANDREW J. — STANFORD UNIVERSITY
- Study coordinator: GENTLES, ANDREW J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.